EARS - Auris Medical shares rise on OligoPhore Lymphoma study results

Auris Medical Holding shares jump ([[EARS]] +8.1%) after the company announced the publication of positive results from an in vivo study demonstrating "significant inhibition of tumor growth" by siRNA knock-down of NF-?B employing its OligoPhore technology in Adult T-cell Leukemia Lymphoma ((ATLL)), a rare and aggressive type of non-Hodgkin’s lymphoma.NF-?B is a protein complex that plays a key role in regulating the immune response to infection and is critical for tumor progression in ATLL.The study showed rapid delivery of siRNA to the tumor and significant reduction of target mRNA and protein expression, which altered the natural history of subsequent tumor progression, the company said.Tumor size, spleen size, and peripheral blood lymphocyte counts were significantly lower in treated mice compared to controls (p<0.01), and tumor growth was reduced to near zero in the most aggressive tumors.

For further details see:

Auris Medical shares rise on OligoPhore Lymphoma study results